13 April 2014

Virus-fighting genes linked to mutations in cancer

Genetic evidence supports role of gene family in cancer development

The APOBEC3A-APOBEC3B genetic deletion is associated with increased burden of presumptive APOBEC-related signatures.The APOBEC3A and APOBEC3B genes are located in tandem on chromosome 22.

The APOBEC3A-APOBEC3B genetic deletion is associated with increased burden of presumptive APOBEC-related signatures.The APOBEC3A and APOBEC3B genes are located in tandem on chromosome 22. [DOI: 10.1038/ng.2955]

zoom

Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development.

Our understanding of the biological processes that cause cancer is limited. UV light and smoking are two well-understood cancer-causing processes. Exposure to either of these processes causes distinguishable patterns of genetic damage, or 'signatures', on the genome that can lead to cancer. All cancer-causing processes leave their own distinct imprint or signature, on the genomes of cancer cells.

The APOBEC family of genes control enzymes that are believed to have evolved in humans to fight off viral infections. Scientists have speculated that these enzymes are responsible for a very distinct signature of mutations that is present in approximately half of all cancer types. Therefore, understanding the cancer-causing process behind this common genetic signature is pivotal for disease control and prevention.

The team studied the genomes of breast cancers in patients with a specific inherited deletion in two of these APOBEC genes. They found that these cancer genomes had a much greater prevalence of the distinct mutational signature that is thought to be driven by the APOBEC family of genes.

" In addition to this APOBEC mediated process, there appear to be many more cancer-causing mutational processes, the underlying nature of which has yet to be understood. "

Professor Sir Mike Stratton

"The increased frequency of this common cancer signature in breast cancer patients with APOBEC gene abnormalities supports our theory that these enzymes play a role in generating this mutational signature," says Dr Serena Nik-Zainal, first author from the Wellcome Trust Sanger Institute.

This genetic deletion is found on chromosome 22 where the APOBEC genes, APOBEC3A and APOBEC3B, sit next to each other. Women with this genetic deletion have previously been reported to be more susceptible to breast cancer.

The team examined 923 samples of breast cancer from women from across the world and found more than 140 people with either one or two copies of the deletion on each chromosome. Breast cancer in women with the deletion had a much greater quantity of mutations of this particular genetic signature.

However, the mutational activity of the APOBEC genes appears to be a double-edged sword. This genetic deletion is much more prevalent in some populations than others: it is found in only 8 per cent of Europeans, but is present in 93 per cent of the population of Oceania. Although this deletion increases risk of cancer development, it also seems to provide a currently unknown advantage in populations where it is more common.

"In addition to this APOBEC mediated process, there appear to be many more cancer-causing mutational processes, the underlying nature of which has yet to be understood," says Professor Sir Mike Stratton, lead author and Director of the Sanger Institute. "Working out what these mutational processes are will have profound implications in the future for how we prevent and treat cancer."

Notes to Editors

Publication details

  • Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.

    Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, Davies HR, Knappskog S, Martin S, Papaemmanuil E, Ramakrishna M, Shlien A, Simonic I, Xue Y, Tyler-Smith C, Campbell PJ and Stratton MR

    Nature genetics 2014;46;5;487-91

Funding

A full list of funding can be found on the paper.

Participating Centres

  • Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA
  • Department of Medical Genetics, Box 134, Addenbrooke's Hospital NHS Trust, Hills Road, Cambridge CB2 0QQ
  • Section of Oncology, Department of Clinical Science, University of Bergen, Norway
  • Department of Oncology, Haukeland University Hospital, Bergen, Norway
  • Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada
  • Regional Genetics Laboratories, Box 143, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ
  • Department of Haematology, University of Cambridge, Cambridge CB2 2XY, UK

The Wellcome Trust Sanger Institute

The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.

Website

The Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.

Website

Contact the Press Office

Don Powell Media and Public Relations Manager
Wellcome Trust Sanger Institute, Hinxton, Cambs, CB10 1SA, UK

Tel +44 (0)1223 496 928
Mobile +44 (0)7753 775 397
Fax +44 (0)1223 494 919
Email press.office@sanger.ac.uk

* quick link - http://q.sanger.ac.uk/9wd0977w